食用菌景气上行,冬虫夏草迎发展机遇 athy Market Virtus ■ 证券研究报告 因 投资评级:看好(首次) 最近 12 月市场表现 159 分析师 手服 SAC 证书编号: S0160525110001 wangcong@ctsec.com 肖珮菁 分析师 SAC 证书编号: S0160524070005 xiaopj@ctsec.com 相关报告 内容目录 | 1 冬虫夏草: 规模化人工培育持续推进…………………………………………………………………………………………………………………………………………………………………………… 4 | | --- | | 1.1 冬虫夏草．产业链持续完善，应用领域广泛 | | 1.2 价格复盘： 稀缺性驱动，野生虫草价格偏强 | | 1.3 政策复盘: 推动技术进步，可持续规范发展 | | 1.4 规模化人工培育冬虫夏草迎发展机遇 | | 2 食用菌：市场格局优化，产能回归理性 . | | 2.1 食用菌行业: 规模持续增长，市场格局优化 . | | 金针菇，竞争格局稳定，价格底部企稳 . 2.2 | | 2.3 双孢菇：龙头份额较高，行业产能稳定 . | | ...

证券日报网讯1月26日，雪榕生物（300511）在互动平台回答投资者提问时表示，《上市公司证券发行 注册管理办法(2025年修正)》第九条和第十三条中对交易所主板上市公司有相关规定，公司为深交所创 业板上市公司。关于定增，公司将按照规定和要求及时履行信息披露义务。 ...

证券日报网讯1月26日，雪榕生物（300511）在互动平台回答投资者提问时表示，二级市场股票价格会 受多种因素影响，希望投资者能够注意防范投资风险。 ...

来源：市场资讯 有投资者在互动平台向雪榕生物提问："请问，人民币升值对公司出口金针菇的利润影响有多大？股价 持续下跌，公司是否会采取相应的措施，来提振股价？谢谢。" 针对上述提问，雪榕生物回应称："尊敬的投资者，您好。目前，公司产品以国内销售为主，汇率波动 未对公司构成重大影响。二级市场股票价格会受多种因素影响，希望投资者能够注意防范投资风险。公 司始终坚持规范运作，也将努力做好经营管理工作，希望能够从业绩出发，为股东创造价值。感谢关 注。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...

Group 1 - Huasheng Tiancheng's AI-related revenue currently accounts for a low proportion of overall revenue, indicating that it does not significantly impact the company's performance [2] - CICC's merger with Dongxing Securities and Xinda Securities is still undergoing audit work, which has not yet been completed [2] - Xinhua Department Store confirmed that there are no undisclosed major matters related to semiconductor asset injections, addressing market rumors [3] Group 2 - Zhong Rare Metals signed a strategic cooperation agreement with Xian Dao Group to enhance market share and industry influence in rare metals [4] - Zhongtian Rocket reported losses in its carbon/carbon thermal field materials business due to intensified competition in the photovoltaic industry [5] - Zhongyuan Nepe proposed to acquire 59% of Zhongyuan Jikean's equity for 143 million yuan, which will make it a wholly-owned subsidiary [5] Group 3 - Jiangxi Copper's subsidiary signed a cooperation agreement with First Quantum Minerals for exploration projects [6] - China Nuclear Power's Jiangsu Xuwei Nuclear Energy Heating Power Plant's first unit is set to pour its first concrete on January 16, 2026 [6] - ST Aowei's stock may be delisted if it continues to trade below par value [6] Group 4 - Triangle Tire plans to invest 3.219 billion yuan in a new high-performance tire project in Cambodia, expected to generate annual revenue of 2.585 billion yuan [7] - Baoxin Technology intends to publicly sell part of its subsidiary's assets, with a valuation of 50.2334 million yuan [7] - Nong Shang Environment's computing infrastructure project has not progressed as planned due to funding issues [8] Group 5 - Golden Dragon Fish plans to transfer stakes in two subsidiaries to Mars China for a total of 60 million USD, which is expected to impact its 2026 earnings significantly [8] - Jin Dao Technology intends to issue convertible bonds to raise up to 306 million yuan for various projects [8] - Aerospace Information expects a net loss of 700 million to 980 million yuan for 2025 due to industry changes [10] Group 6 - Tianji Co. forecasts a net profit of 70 million to 105 million yuan for 2025, recovering from a previous loss [10] - Muyuan Foods anticipates a net profit decrease of 12.2% to 17.79% for 2025 [11] - SAIC Group expects a net profit increase of 438% to 558% for 2025, driven by sales growth [12] Group 7 - Haolaike expects a significant drop in net profit for 2025, projecting a decrease of 75.16% to 83.23% [13] - Hainan Development anticipates a net loss of 440 million to 565 million yuan for 2025 [13] - Shuangliang Energy expects to report a loss for 2025 [14] Group 8 - Aijian Group also anticipates a loss for 2025 [14] - Meijin Energy forecasts a net loss of 850 million to 1.25 billion yuan for 2025 [14] - Kunlun Wanwei expects to report a loss for 2025 [14] Group 9 - Xue Rong Biological expects a net profit of 29 million to 40 million yuan for 2025, recovering from a previous loss [15] - Xin Nuo Wei anticipates a net loss of 170 million to 255 million yuan for 2025 due to increased R&D expenses [15] - Shengnuo Biological expects a net profit increase of 204.42% to 280.53% for 2025 [16] Group 10 - Longyuan Construction forecasts a net loss of 1 billion to 1.5 billion yuan for 2025 [17] - Kosen Technology expects a net loss of 245 million to 330 million yuan for 2025 [17] - Daqian Ecology anticipates a net loss of 100 million to 120 million yuan for 2025 [17] Group 11 - Lianfa Co. expects a net profit increase of 38.92% to 58.77% for 2025 [18] - Chongqing Steel anticipates a net loss of 2.5 billion to 2.8 billion yuan for 2025, but expects to reduce losses compared to the previous year [18] - Tongxing Technology forecasts a net profit increase of 74.2% to 125.44% for 2025 [19] Group 12 - Siyuan Electric expects a net profit of 3.163 billion yuan for 2025, a 54.35% increase year-on-year [19] - Luoyang Molybdenum expects a net profit increase of 47.8% to 53.71% for 2025 [20] - Nawei Technology anticipates a net profit increase of 54.51% to 75.03% for 2025 [20] Group 13 - Jingjia Micro expects a net loss of 120 million to 180 million yuan for 2025 [21] - Southwest Securities forecasts a net profit increase of 47% to 57% for 2025 [22] - Wankai New Materials expects a net profit of 156 million to 203 million yuan for 2025, recovering from a previous loss [22] Group 14 - Yilian Network anticipates a slight decrease in net profit for 2025, projecting a decline of 0% to 4% [23] - Baofeng Energy expects a net profit increase of 73.57% to 89.34% for 2025 [23] - Sanmei Co. forecasts a net profit increase of 155.66% to 176.11% for 2025 [23] Group 15 - Zhenyu Technology expects a net profit increase of 96.89% to 116.58% for 2025 [24] - Fute Technology anticipates a net profit increase of 121.98% to 164.26% for 2025 [24] - Guoli Electronics expects a net profit increase of 124.89% to 164.57% for 2025 [24] Group 16 - Shenyu Co. expects a slight decrease in net profit for 2025, projecting a decline of 0.05% to 11.37% [25] - Rongchang Biological plans to increase its share repurchase price limit to 116 yuan per share [26] - Defu Technology plans to repurchase shares for 75 million to 150 million yuan [26] Group 17 - ST Chengchang's stock will resume trading on January 16 after completing a trading fluctuation investigation [27] - Zhi Te New Materials will also resume trading on January 16 after confirming no major changes in business operations [27] - Lio Co. will suspend trading starting January 16 for stock fluctuation investigation [27]

证券日报网讯 1月15日，雪榕生物发布2025年度业绩预告称，公司预计2025年度归属于上市公司股东的 净利润为2，900万元至4，000万元。 （文章来源：证券日报） ...

Core Viewpoint - Xuerong Bio (300511) expects a significant turnaround in its financial performance, projecting a net profit of 29 million to 40 million yuan for 2025, compared to a loss of 617 million yuan in the same period last year [1] Group 1: Financial Performance - The company anticipates a net profit of 29 million to 40 million yuan for 2025 [1] - In the previous year, the company reported a loss of 617 million yuan [1] Group 2: Industry Outlook - The edible mushroom industry is expected to stabilize and recover in the second half of 2025, leading to an increase in product prices [1] - The improvement in product prices is expected to enhance the company's gross margin [1] Group 3: Company Developments - Xuerong Bio has made breakthrough progress with a new strain of white enoki mushrooms, leveraging its seed source advantages [1] - The company has significantly increased its capacity utilization and reduced overall costs as a result of these advancements [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of between 29 million and 40 million yuan in 2025, marking a turnaround from losses in previous years [1] Group 1: Industry Outlook - The edible mushroom industry is anticipated to stabilize and recover in the second half of 2025 after a prolonged adjustment period, leading to an increase in the prices of main products and an improvement in gross margins [1] Group 2: Company Performance Drivers - Breakthroughs in new strains of white enoki mushrooms are expected to significantly enhance production capacity utilization and reduce overall costs in the second half of 2025 [1] - The company is actively implementing quality improvement and efficiency enhancement measures, resulting in a reduction of approximately 45 million yuan in period expenses year-on-year [1] Group 3: Non-Recurring Gains - The company estimates that non-recurring gains will contribute approximately 24 million yuan to net profit in 2025, primarily from government subsidies and asset disposal gains [1]

Core Viewpoint - Snow Rong Biological (300511.SZ) expects a net profit attributable to shareholders of 29 million to 40 million yuan in 2025, marking a turnaround from losses, with a net profit excluding non-recurring gains and losses projected at 5 million to 16 million yuan, also indicating a return to profitability [1] Industry Summary - The edible mushroom industry has undergone a prolonged adjustment period, with expectations for stabilization and recovery in the second half of 2025, driven by an increase in the prices of main products, which will enhance gross margins [1] Company Summary - In the second half of 2025, breakthroughs in new strains of white enoki mushrooms are anticipated, leveraging the company's advantages in seed sources, leading to a significant increase in capacity utilization and a notable reduction in overall costs [1] - The company is actively pursuing quality improvement and efficiency enhancement initiatives, with strict control over expense spending, resulting in a year-on-year reduction of approximately 45 million yuan in period expenses [1] - The expected impact of non-recurring gains and losses on net profit for 2025 is estimated at around 24 million yuan, primarily from government subsidies and asset disposal gains [1]

Financial Performance - The company expects a net profit of between 29 million and 40 million CNY for the year 2025, a significant recovery from a loss of 617 million CNY in the same period last year[5]. - The net profit after deducting non-recurring gains and losses is projected to be between 5 million and 16 million CNY, compared to a loss of 634 million CNY in the previous year[5]. - The company anticipates a non-recurring gain of approximately 24 million CNY impacting net profit, primarily from government subsidies and asset disposal gains[8]. - The financial data provided is a preliminary estimate and will be finalized in the 2025 annual report, pending audit by the accounting firm[9]. Industry Outlook - The edible mushroom industry is expected to stabilize and recover in the second half of 2025, leading to an increase in product prices and improved gross margins[7]. Operational Improvements - The company achieved a breakthrough in the new strain of white enoki mushroom, significantly increasing production capacity utilization and reducing overall costs[8]. - The company has reduced period expenses by approximately 45 million CNY through strict cost control measures[8].